Development and Validation of an Ultrasound-Based Clinical Radiomics Nomogram for Diagnosing Gouty Arthritis.

Ultrasound Med Biol

Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, China; Fuzhou University Affiliated Provincial Hospital, Department of Ultrasound, Fuzhou, Fujian Province, China. Electronic address:

Published: January 2025

Objective: This study aimed to develop and validate a diagnostic model for gouty arthritis by integrating ultrasonographic radiomic features with clinical parameters.

Methods: A total of 604 patients suspected of having gouty arthritis were enrolled and randomly divided into a training set (n = 483) and a validation set (n = 121) in a 4:1 ratio. Univariate and multivariate analyses were conducted on the clinical data to identify statistically significant clinical features for constructing an initial diagnostic model. Key radiomic features were identified in the training set using least absolute shrinkage and selection operator (LASSO) regression analysis to establish a radiomic model. A composite clinicoradiomic nomogram was then developed by combining clinical (such as C-reactive protein, erythrocyte sedimentation rate and uric acid level) and radiomic features through logistic regression. The predictive performance of the clinical model, radiomic model and clinicoradiomic nomogram was evaluated in the validation set using receiver operating characteristic curves, calibration curves and decision curve analysis.

Results: The clinicoradiomic nomogram, which integrated imaging features and clinical characteristics via logistic regression, demonstrated superior predictive performance in the validation set, with an area under the curve (AUC) of 0.936 (95% CI: 0.885-0.986), surpassing both clinical (AUC = 0.924; 95% CI: 0.873-0.976) and radiomic models (AUC = 0.828; 95% CI: 0.738-0.918) alone. Decision curve analysis further confirmed the clinical utility of this model, particularly in differentiating between gouty and non-gouty arthritis.

Conclusion: Compared with standalone clinical or radiomic models, the ultrasonography-based clinicoradiomic model exhibited enhanced predictive accuracy for diagnosing gouty arthritis, presenting a novel and promising approach for the early diagnosis and management of gouty arthritis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ultrasmedbio.2024.12.009DOI Listing

Publication Analysis

Top Keywords

gouty arthritis
20
radiomic features
12
validation set
12
clinicoradiomic nomogram
12
clinical
10
diagnosing gouty
8
diagnostic model
8
features clinical
8
training set
8
radiomic model
8

Similar Publications

Development and Validation of an Ultrasound-Based Clinical Radiomics Nomogram for Diagnosing Gouty Arthritis.

Ultrasound Med Biol

January 2025

Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, China; Fuzhou University Affiliated Provincial Hospital, Department of Ultrasound, Fuzhou, Fujian Province, China. Electronic address:

Objective: This study aimed to develop and validate a diagnostic model for gouty arthritis by integrating ultrasonographic radiomic features with clinical parameters.

Methods: A total of 604 patients suspected of having gouty arthritis were enrolled and randomly divided into a training set (n = 483) and a validation set (n = 121) in a 4:1 ratio. Univariate and multivariate analyses were conducted on the clinical data to identify statistically significant clinical features for constructing an initial diagnostic model.

View Article and Find Full Text PDF

Advances in the use of nanotechnology for treating gout.

Nanomedicine (Lond)

January 2025

Weihai Marine Organism & Medical Technology Research Institute, Harbin Institute of Technology, Weihai, P. R. China.

Gout is a commonly occurring form of inflammatory arthritis caused by persistently elevated levels of uric acid. Its incidence rate rises with the increases of living standards and poor dietary habits, which has a considerable impact on the quality of life of the patients. Although there is a wide assortment of drugs available for the management of gout, the effectiveness and security of these drugs are limited by their poor chemical stability and insufficient targeting.

View Article and Find Full Text PDF

The role of celastrol in inflammation and diseases.

Inflamm Res

January 2025

Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.

Celastrol is one of the main active ingredients extracted from the plant Tripterygium wilfordii Hook F. A growing number of studies have shown that celastrol has various pharmacological effects, including anti-inflammation, anti-rheumatism, treatment of neurodegenerative diseases, and anti-tumor. This article systematically summarized the mechanism and role of celastrol in lipid metabolism and obesity, rheumatoid arthritis (RA), osteoarthritis (OA), gouty arthritis, inflammatory bowel disease, neurodegenerative diseases, and cancer and other diseases (such as diabetes, respiratory-related diseases, atherosclerosis, psoriasis, hearing loss, etc.

View Article and Find Full Text PDF

Monosodium urate crystal accumulation in the joints is the cause of gout, an inflammatory arthritis that is initiated by elevated serum uric acid levels. It is the most prevalent form of inflammatory arthritis, affecting millions worldwide, and requires effective treatments. The necessity for alternatives with fewer side effects is underscored by the frequent adverse effects of conventional therapies, such as urate-lowering drugs.

View Article and Find Full Text PDF

Discovery of selective ROCK2 inhibitors with free radical scavenging ability for the treatment of gouty arthritis.

Mol Divers

January 2025

Key Laboratory of Structure-Based Drugs Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, PR China.

ROCK inhibitors can inhibit IL-1β and NLRP3, and their therapeutic potential for osteoarthritis and rheumatoid arthritis has been confirmed, but their impact on gouty arthritis has not been reported yet. By hybridization the structure of Edaravone, a series of ROCK inhibitors with pyrazolone scaffold were designed and synthesized. RM-04 has acceptable selective ROCK2 inhibitory activity with an IC of 4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!